Qiao Jinggui, Zhao Congya
Department of Gastroenterology, Xi'an Gaoxing Hospital Xi'an 710000, Shaanxi Province, China.
Am J Transl Res. 2021 Aug 15;13(8):9485-9494. eCollection 2021.
To analyze the therapeutic efficacy of adenosylmethionine on viral hepatitis and the related factors inducing disease.
From May 2018 to April 2019, 137 patients with viral hepatitis who received treatment in our hospital were selected and assigned to two groups according to different treatment methods. In the control group (CG), 61 cases were treated with routine liver protection and enzyme reduction. In the research group, 76 cases were treated with adenosylmethionine on the basis of the CG. After therapy, the total response rate was analyzed in both groups, and the adverse reactions were observed during the treatment. The liver function indexes [albumin (ALB), alanine aminotransferase (ALT), glutamic acid transaminase (AST) and total bilirubin (TBIL)], liver fiber indicators [hyaluronic acid (HA), laminin (LN), type III procollagen (PCIII), type IV collagen (IV-C)], inflammatory factors [interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)] were compared in both groups before and after therapy. ELISA was applied to detect inflammatory factors in both groups before and after treatment. Logistic analysis was applied to analyze the independent risk factors affecting the curative effect of patients with viral hepatitis.
After therapy, the total response rate of patients in RG was obviously higher than that in CG; The total incidence of adverse effects in RG was obviously lower than that in CG; The improvement of liver function indexes and liver fiber indicators in RG was better than that in CG; The expression of inflammatory factors in RG was obviously lower than that in CG. Logistic analysis revealed that patients' age (>40 years old), drinking history, family history, low improvement of hepatic function and hepatic fibrosis, high level of inflammatory cytokines and routine treatment were independent prognostic factors affecting patients with viral hepatitis.
Adenosylmethionine intervention can promote disease recovery, reduce inflammation level and improve liver function damage for patients with viral hepatitis.
分析腺苷蛋氨酸对病毒性肝炎的治疗效果及诱发疾病的相关因素。
选取2018年5月至2019年4月在我院接受治疗的137例病毒性肝炎患者，根据不同治疗方法分为两组。对照组（CG）61例采用常规保肝降酶治疗。研究组76例在CG基础上加用腺苷蛋氨酸治疗。治疗后，分析两组的总有效率，并观察治疗期间的不良反应。比较两组治疗前后的肝功能指标[白蛋白（ALB）、丙氨酸氨基转移酶（ALT）、谷氨酸转氨酶（AST）和总胆红素（TBIL）]、肝纤维化指标[透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PCIII）、Ⅳ型胶原（IV-C）]、炎症因子[白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）]。采用酶联免疫吸附测定法（ELISA）检测两组治疗前后的炎症因子。应用Logistic分析探讨影响病毒性肝炎患者疗效的独立危险因素。
治疗后，研究组患者的总有效率明显高于对照组；研究组不良反应总发生率明显低于对照组；研究组肝功能指标和肝纤维化指标的改善情况优于对照组；研究组炎症因子表达明显低于对照组。Logistic分析显示，患者年龄（>40岁）、饮酒史、家族史、肝功能和肝纤维化改善程度低、炎症细胞因子水平高及常规治疗是影响病毒性肝炎患者预后的独立因素。
腺苷蛋氨酸干预可促进病毒性肝炎患者疾病恢复，降低炎症水平，改善肝功能损害。
